Literature DB >> 22695393

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.

Robert J Gillies1, Daniel Verduzco, Robert A Gatenby.   

Abstract

All malignant cancers, whether inherited or sporadic, are fundamentally governed by Darwinian dynamics. The process of carcinogenesis requires genetic instability and highly selective local microenvironments, the combination of which promotes somatic evolution. These microenvironmental forces, specifically hypoxia, acidosis and reactive oxygen species, are not only highly selective, but are also able to induce genetic instability. As a result, malignant cancers are dynamically evolving clades of cells living in distinct microhabitats that almost certainly ensure the emergence of therapy-resistant populations. Cytotoxic cancer therapies also impose intense evolutionary selection pressures on the surviving cells and thus increase the evolutionary rate. Importantly, the principles of Darwinian dynamics also embody fundamental principles that can illuminate strategies for the successful management of cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22695393      PMCID: PMC4122506          DOI: 10.1038/nrc3298

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  122 in total

Review 1.  Genomic instability--an evolving hallmark of cancer.

Authors:  Simona Negrini; Vassilis G Gorgoulis; Thanos D Halazonetis
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

2.  Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.

Authors:  Jihye Yun; Carlo Rago; Ian Cheong; Ray Pagliarini; Philipp Angenendt; Harith Rajagopalan; Kerstin Schmidt; James K V Willson; Sandy Markowitz; Shibin Zhou; Luis A Diaz; Victor E Velculescu; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos
Journal:  Science       Date:  2009-08-06       Impact factor: 47.728

3.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.

Authors:  Anne Le; Charles R Cooper; Arvin M Gouw; Ramani Dinavahi; Anirban Maitra; Lorraine M Deck; Robert E Royer; David L Vander Jagt; Gregg L Semenza; Chi V Dang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

4.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Authors:  Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope Rugo; George Sledge; Maria Koehler; Catherine Ellis; Michelle Casey; Svetislava Vukelja; Joachim Bischoff; Jose Baselga; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

Review 5.  Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors.

Authors:  Jean-Francois Chatal; Francois Davodeau; Michel Cherel; Jacques Barbet
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

Review 6.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

7.  In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks.

Authors:  Hui Ying Zhang; Kathy Hormi-Carver; Xi Zhang; Stuart J Spechler; Rhonda F Souza
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

8.  Lessons from applied ecology: cancer control using an evolutionary double bind.

Authors:  Robert A Gatenby; Joel Brown; Thomas Vincent
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

9.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Authors:  F M Iwamoto; L E Abrey; K Beal; P H Gutin; M K Rosenblum; V E Reuter; L M DeAngelis; A B Lassman
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

Review 10.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Authors:  Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2009-08-07       Impact factor: 20.096

View more
  261 in total

1.  Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia.

Authors:  Andrii I Rozhok; Jennifer L Salstrom; James DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

Review 2.  Ecological paradigms to understand the dynamics of metastasis.

Authors:  Sarah R Amend; Sounak Roy; Joel S Brown; Kenneth J Pienta
Journal:  Cancer Lett       Date:  2015-10-10       Impact factor: 8.679

Review 3.  How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity.

Authors:  Padmashree C G Rida; Guilherme Cantuaria; Michelle D Reid; Omer Kucuk; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

4.  Enhancement of radiation effect on cancer cells by gold-pHLIP.

Authors:  Michael P Antosh; Dayanjali D Wijesinghe; Samana Shrestha; Robert Lanou; Yun Hu Huang; Thomas Hasselbacher; David Fox; Nicola Neretti; Shouheng Sun; Natallia Katenka; Leon N Cooper; Oleg A Andreev; Yana K Reshetnyak
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

Review 5.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

6.  Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results.

Authors:  Mu Zhou; Lawrence Hall; Dmitry Goldgof; Robin Russo; Yoganand Balagurunathan; Robert Gillies; Robert Gatenby
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

Review 7.  Life history trade-offs in cancer evolution.

Authors:  C Athena Aktipis; Amy M Boddy; Robert A Gatenby; Joel S Brown; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2013-11-11       Impact factor: 60.716

Review 8.  Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Authors:  Samuel T Workenhe; Karen L Mossman
Journal:  Mol Ther       Date:  2013-10-19       Impact factor: 11.454

Review 9.  Applications of pHLIP Technology for Cancer Imaging and Therapy.

Authors:  Linden C Wyatt; Jason S Lewis; Oleg A Andreev; Yana K Reshetnyak; Donald M Engelman
Journal:  Trends Biotechnol       Date:  2017-04-21       Impact factor: 19.536

10.  New approach in lung cancer radiotherapy offers better normal tissue sparing.

Authors:  Ivaylo B Mihaylov
Journal:  Radiother Oncol       Date:  2016-09-28       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.